Zytiga Resistant Prostate Cancer (ZRPC) is emerging as a distinct form of prostate cancer that is completely androgen independant. Zytiga works to block all androgen production in the human body by selectively inhibiting the cytochrome P450 enzyme CYP17. When a patient has become Zytiga resistant then the prostate cancer must be able to survive in the complete absence of androgens. At this stage for the cancer to be progressing the tumour cells must have evolved a means of survival and growth in the absence of androgens. Thus ZRPC is the ultimate form of castrate resistant prostate cancer CRPC.
Zytiga resistance is believed to be mediated by mutations in the androgen receptor through splice varients that can result in permanantly signalling androgen receptors. One splice varient is thought to have no ligand binding domain and can signal to grow without androgen stimulation. So blocking androgens is useless for this type of cancer, but you do not know if you have this type of cancer until you have tried Zytiga and become resistant i.e classified as ZRPC.
What are the treatment options for Zytiga Resistant Prostate Cancer (ZRPC) ?
1. Salvestrol Platinum 2000
2. Cabozantinib XL-184
3. Enzalutamide MDV3100
4. Quercetin
5. Bromelain
6. Trametinib
7. Pazopanib
8. Graviola
9. Regorafenib
No comments:
Post a Comment